International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT


Christians Uwe 150x200

Program Leader

Uwe Christians
Denver, CO, USA


Contact Us
Scientific Committees
Immunosuppressives Drugs Committee
Biomarkers Working Group

Background & Purpose of the Committee

  • To promote the study of promising biomarkers in the detection of individual immune response and in the prediction of the risk of rejection, immunosuppressant–related toxicity and graft dysfunction;
  • To enhance cross validation biomarkers in independent populations and different laboratories, using the same standardized methodology, to guide therapy in clinical practice, to prevent drug-induced adverse effects and improve treatment efficacy;
  • To coordinate specific research on biomarkers of immunosuppression, as a complement to pharmacokinetics, and to develop improved models for better multiple PK/PD data analysis correlation and their impact on clinical outcome;
  • To encourage consensus documents on PK/PD monitoring by the BWG for the promotion of new approaches in immunosuppressive drug selection and adjustment, to achieve safer personalized treatment; and
  • To participate in the design of prospective multicentric clinical studies, as a part of a multidisciplinary group of specialist, for clinical validation of biomarkers of immunosuppression.

Committee Initiatives

  • To perform a Consensus Document and to edit a Special Issue of Therapeutic Drug Monitoring on Biomarkers of Immunosuppression in Transplantation
    Project Coordination: Mercè Brunet, Michael Oellerich
  • Submission of materials for the educational area of the IATDMCT website
  • BWG of the Immunosuppressive Drugs Committee representation at scientific meetings and congresses
  • Coordination of a European Grant Applied for FP7-HEALTH-2012 two-stage. -Innovation-1 HEALTH.2012.1.4-1: Innovative approaches to Solid Organ Transplantation: “Clinical Application of Biomarkers for Personalized Immunosuppression in Transplantation”. This project involves several members of the Biomarker Working Group.
  • Preliminary organization of the III European Symposium on Biomarkers of Immunosuppression that involved the active participation of BWG members (IATDMCT auspices)
  • Participation on the Symposium S2502: Pharmacodynamic Monitoring
    Biomarkers of Immunosuppression in Transplantation
    Mercè Brunet, Leader of the Biomarker Working Group of the Scientific Committee of IDs
    Moderator: Leslie M. Shaw
    XIII Congress of the IATDMCT Salt Lake City, September 2013
  • IV Symposium on Biomarkers of Immunosuppression and Clinical Outcome in Transplantation: New Approaches on TDM of Immunosuppressive Drugs.
    Barcelona, December 11-12 2014
    Scientific Coordination: Mercè Brunet and Pierre Wallemacq